retatrutide case study for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Retatrutide, a GIP, GLP-1 and

Individuals with obesity, both with and without T2DM, show increased risks for gastrointestinal bleeding when treated with GLP-1R agonists combined with aspirin [140]

Results still clinically significant, just potentially in lower range of expectations

The Best GLP-1 Injection Sites Choosing the right spot is the easiest way to keep injections comfortable and effective

You should not take retatrutide if you have: A personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 A history of pancreatitis Severe gastrointestinal disease, including gastroparesis Known hypersensitivity to any component of the drug You should use extreme caution and only proceed under close medical supervision if you have: Gallbladder disease or a history of gallstones Kidney disease, since dehydration from GI side effects can accelerate kidney damage Diabetic retinopathy, as rapid glucose changes can worsen it A history of eating disorders, since appetite suppression this powerful can interact badly with disordered eating patterns Retatrutide is also not approved for use in pregnancy